Reviews/P2Y12 Antiplatelets/Clopidogrel is noninferior to ticagrelor in elderly ACS patients
Tca · P2Y12-TCA-03 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
In people aged about 70 and older who have had a heart attack or unstable chest pain, two blood-thinning drugs were compared: clopidogrel and the more potent ticagrelor. The one dedicated randomised trial found that clopidogrel caused fewer bleeds and did not increase the combined count of deaths, heart attacks, strokes and bleeds [1]. Several real-world patient databases pointed the same way for the overall balance of benefit and harm [7][8][10], while a frailty study showed only weak trends [9]. The catch is that ticagrelor still prevented more heart attacks and strokes on its own [7][8], so clopidogrel looks equal only once its lower bleeding is counted in. The panel treated the finding as supported but not settled, because it leans on a single open trial and on observational data that cannot rule out patient-selection effects.
The sole dedicated randomised trial met its pre-specified net-clinical-benefit non-inferiority endpoint for clopidogrel in patients aged 70 or older with NSTE-ACS, with fewer bleeds (18% vs 24%; hazard ratio 0.71, 95% CI 0.54 to 0.94) [1]. Three observational cohorts converge on a neutral overall effect: a similar primary ischaemic outcome in patients 80 or older (HR 0.97, 95% CI 0.88 to 1.06) [7], neutral NACE and mortality in those 75 or older [8], and no difference in net clinical benefit (17.2% vs 15.1%, adjusted HR 1.05) or atherothrombotic outcomes in a genotype-defined subgroup [10]. A Medicare frailty cohort showed only non-significant trends [9]. Across these, ticagrelor consistently lowered purely ischaemic endpoints: MI (HR 0.80) and stroke (HR 0.72) in [7], and MACE (HR 0.82) and MI (HR 0.43) in [8]. The contested point: The division is over what noninferior covers. Clopidogrel is equivalent only on the combined net-benefit endpoint, where its lower bleeding offsets ticagrelor's advantage; on ischaemic endpoints alone ticagrelor is superior [7][8]. The non-RCT support is also observational, so confounding by indication, with higher-bleeding-risk patients channelled to clopidogrel, cannot be excluded [7][8][9].
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from P2Y12 Antiplatelets, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Non-inferiority rests on a single open-label RCT [1] (N=1002) with a 2% margin and p=0.03; the 47% vs 22% discontinuation imbalance (ticagrelor vs clopidogrel) can bias an ITT open-label design toward the comparator.
"Noninferior" is outcome-contingent: on purely ischaemic endpoints ticagrelor is superior ([8] MACE HR 0.82, MI HR 0.43; [7] lower MI and stroke), so the claim is defensible only for net clinical benefit where bleeding offsets.
Where it remains uncertain. Ticagrelor still lowers MI and stroke [7] and MACE and MI [8], and the support beyond the single open-label RCT is observational and open to confounding.
Aleatory
The net-benefit difference in [1] is -4% (95% CI -10.0 to 1.4) with p=0.03 against a 2% margin, so sampling variation leaves the result close to the boundary.
Epistemic
Randomised evidence specific to the elderly is limited to [1]; [7]'s authors explicitly state a randomised trial in this population is still needed.
Inferential
Premature discontinuation was 238 (47%) on ticagrelor versus 112 (22%) on clopidogrel in an ITT open-label design [1], which can bias toward the comparator.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Only dedicated RCT; directly establishes net-benefit non-inferiority of clopidogrel in >=70 NSTE-ACS.
“Co-primary net clinical benefit outcome was non-inferior for the use of clopidogrel (139 [28%]) versus ticagrelor (161 [32%]; absolute risk difference -4%, 95% CI -10·0 to 1·4; p=0·03 for non-inferiority).”
Panel auditInternal validity: medium · scope of inference: Patients aged 70 years or older with NSTE-ACS; net clinical benefit combining death, MI, stroke and bleeding over 12 months.Key limitations: open-label · high differential ticagrelor discontinuation · net endpoint mixes ischaemic and bleeding events · NSTE-ACS only
Large registry in >=80; ischaemic composite equivalent, with ticagrelor carrying higher death and bleeding.
“In patients ≥80 years, the incidence of the primary ischemic outcome (hazard ratio [HR], 0.97 [95% CI, 0.88-1.06]) was similar for ticagrelor- and clopidogrel-treated patients.”
Panel auditInternal validity: medium · scope of inference: Patients aged 80 or older discharged after MI, primary ischaemic composite and bleeding at 1 year.Key limitations: observational confounding by indication · composite masks divergent components (higher death but lower MI/stroke with ticagrelor) · registry outcomes
Registry in >=75 ACS PCI; neutral net/mortality supports the claim but flags a ticagrelor ischaemic-efficacy edge.
“Ticagrelor showed neutral effect on NACE and mortality (HR 0.98; 0.63-1.52, p = 0.94 and HR 0.38; 0.14-1.04, p = 0,06), reduced risk of MACE and MI (HR 0.82; 0.23-0.91, p = 0.03 and HR 0.43; 0.14-0.89, p = 0.04) and increased risk of BARC 3-5 bleeding (HR 2.14; 1.19-3.85, p = 0.001).”
Panel auditInternal validity: low · scope of inference: ACS patients aged 75 and older (and >=85) after PCI, mortality, MACE, MI, bleeding and net clinical benefit.Key limitations: conflicting direction across endpoints · observational confounding · wide CIs · unequal group sizes
Large cohort showing only non-significant trends, consistent with no clear superiority of ticagrelor over clopidogrel in older adults.
“There was a trend toward a modest reduction in risk of major adverse cardiovascular events and a trend toward a modest increase in risk of major bleeding with ticagrelor compared with clopidogrel in the nonfrail cohort.”
Panel auditInternal validity: medium · scope of inference: Medicare beneficiaries aged 65 and older with ACS after PCI, MACE and major bleeding, by frailty status.Key limitations: observational claims data · trends only, all CIs cross 1 · frail subgroup underpowered
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One open-label RCT plus consistent observational corroboration carries net-benefit non-inferiority, but a borderline margin, confounding risk, and a ticagrelor ischaemic-efficacy signal keep it below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No blinded randomised elderly head-to-head. Non-inferiority rests on a single open-label trial [1] whose 47% vs 22% discontinuation imbalance can bias an ITT analysis toward clopidogrel. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A blinded (or double-dummy) randomised trial of ticagrelor versus clopidogrel restricted to patients 70 or older with ACS, powered on net clinical benefit.
Open question: Is clopidogrel non-inferior to ticagrelor on net clinical benefit in elderly ACS when treatment allocation is blinded? Why it is still open: The only dedicated RCT [1] is open-label with a marked discontinuation imbalance that can bias the ITT estimate toward the comparator.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19